Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

ClinicalTrials.gov ID: NCT03704714

Public ClinicalTrials.gov record NCT03704714. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With R-CHOP in a Cohort of Patients With DLBCL/tFL/ High Grade B-NHL

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase I/II trial studies the side effects and best dose of nivolumab and how well it works when giving together with combination chemotherapy in treating participants with diffuse large B-cell lymphoma. Monoclonal antibodies, such as nivolumab, interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and combination chemotherapy may work better in treating participants with diffuse large B-cell lymphoma.

Study identification

NCT ID: NCT03704714
Recruitment status: Suspended
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Northwestern University; Other
Enrollment: 30 participants

Conditions and interventions

Conditions

Interventions

Drug · Biological · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 19, 2018
Primary completion: Dec 10, 2024
Completion: Jun 10, 2025
Last update posted: Aug 14, 2022

2018 – 2025

United States locations

U.S. sites: 4
U.S. states: 1
U.S. cities: 3

Facility	City	State	ZIP	Site status
Northwestern University	Chicago	Illinois	60611	—
Rush University Medical Center	Chicago	Illinois	60612	—
Northwestern University- Lake Forest Hospital	Lake Forest	Illinois	60045	—
Northwestern Medicine: Delnor, DuPage, Warrenville, Kishwaukee (West Region)	Warrenville	Illinois	60555	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03704714, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 14, 2022 · Synced Sep 11, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03704714 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →